相关实验视频
Updated: Jun 17, 2025

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
21.6K
针对GRP78的小分子在培养内皮细胞中减轻了抗GRP78自身抗体介导的组织因子前凝剂活性
Jack Chen1, Edward G Lynn1, Hitesh Sharma1
1Department of Medicine, Division of Nephrology, McMaster University, The Research Institute of St. Joe's Hamilton and The Hamilton Center for Kidney Research, Hamilton, Ontario, Canada.
Journal of thrombosis and haemostasis : JTH
|August 7, 2024
概括
抗GRP78自身抗体会增加组织因子对内皮细胞的血凝活性,从而导致血栓形成. 新型GRP78结合剂显示出治疗动脉栓塞性疾病的潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 血管生物学 血管生物学
- 生物化学 生化学
背景情况:
- 细胞表面78kDa的葡萄糖调节蛋白 (csGRP78) 影响内皮细胞 (ECs) 中的组织因子 (TF) 凝血活性 (PCA).
- 循环中的抗GRP78自身抗体与csGRP78上的特定表位体结合,可以增强TF PCA.
研究的目的:
- 调查抗GRP78自身抗体与csGRP78的接触如何影响ECs.
- 阐明影响TF PCA背后的机制.
- 为了确定针对这种相互作用的潜在治疗剂.
主要方法:
- 免疫光染色用于检测csGRP78.8.
- TF PCA对用抗GRP78自身抗体治疗的人类EC进行了测定.
- 使用Fura 2-AM试验量化细胞内 (Ca2+) 水平.
- 通过人工智能驱动的GRP78结合小分子的识别.
- 通过ELISA测试来评估GRP78粘合剂的有效性.
主要成果:
- 反GRP78自身抗体在TNFα治疗的EC中增加了TF PCA,在ER压力期间效果增强.
- 自体抗体治疗导致细胞内Ca2+水平升高.
- 一个GRP78结合剂,B07*,减少了自身抗体诱导的TF PCA.
结论:
- 反GRP78自身抗体促进TF PCA,导致血栓形成.
- 新型GRP78结合剂为动脉瘤性疾病提供了潜在的治疗策略.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
657
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
657
Clot Retraction and Fibrinolysis
5.1K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.1K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
502
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
502

